Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile-Reference-Cited by-同舟云学术

Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile

Published:2009-08-26 Issue:2 Volume:331 Page:740-751
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Gavaldà Amadeu,Miralpeix Montserrat,Ramos Israel,Otal Raquel,Carreño Cristina,Viñals Marisa,Doménech Teresa,Carcasona Carla,Reyes Blanca,Vilella Dolors,Gras Jordi,Cortijo Julio,Morcillo Esteban,Llenas Jesús,Ryder Hamish,Beleta Jorge

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference38 articles.

1. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder

2. Cholinergic Pathways in the Lungs and Anticholinergic Therapy for Chronic Obstructive Pulmonary Disease

3. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD

4. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

5. Novel long-acting bronchodilators for COPD and asthma

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020–2023;Lung;2024-02-06

2. Is it preferable to administer a bronchodilator once- or twice-daily when treating COPD?;Respiratory Medicine;2023-11

3. Design and synthesis of 2-(2,2-diarylethyl)-cyclamine derivatives as M3 receptor antagonists and functional evaluation on COPD;Bioorganic Chemistry;2023-02

4. Comparison of efficacy and side effects of fixed-dose combination of Aclidinium/Formoterol and Monotherapy of Aclidinium or Formoterol in COPD: A meta-analysis;Heart & Lung;2022-01

5. Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers;Respiratory Research;2021-10-22